Tobacco Use and the Cancer Patient
Tobacco Use and the Cancer Patient Graham W. Warren Benjamin A. Toll Irene M. Tamí-Maury Ellen R. Gritz INTRODUCTION Tobacco is commonly described as the largest preventable cause of cancer….
Assessment of Clinical Response
Assessment of Clinical Response Antonio Tito Fojo Susan E. Bates INTRODUCTION Approaches to response assessments have become increasingly important over the past decade as the drug development pipeline has steadily…
Monoclonal Antibodies
Monoclonal Antibodies Hossein Borghaei Matthew K. Robinson Gregory P. Adams Louis M. Weiner INTRODUCTION Antibody-based therapeutics are important components of the cancer therapeutic armamentarium. Early antibody therapy studies attempted to…
Antiangiogenesis Agents
Antiangiogenesis Agents Cindy H. Chau William Douglas Figg Sr. INTRODUCTION Blood vessels are indispensable for tumor growth and metastasis, and the formation of a new network of blood vessels from…
Hormonal Agents
Hormonal Agents Matthew P. Goetz Charles Erlichman Charles L. Loprinzi Manish Kohli INTRODUCTION Hormonal agents are commonly used as a treatment of hormonally responsive cancers, such as breast, prostate, or…
Miscellaneous Chemotherapeutic Agents
Miscellaneous Chemotherapeutic Agents M. Sitki Copur Scott Nicholas Gettinger Sarah B. Goldberg Hari A. Deshpande HOMOHARRINGTONINE AND OMACETAXINE Homoharringtonine and its congener, harringtonine, are cephalotaxine esters isolated from the evergreen…
Poly (ADP-ribose) Polymerase Inhibitors
Poly (ADP-ribose) Polymerase Inhibitors Alan Ashworth INTRODUCTION Cancer cells may harbor defects in DNA repair pathways leading to genomic instability. This can foster tumorigenesis but also provides a weakness that…
Proteasome Inhibitors
Proteasome Inhibitors Christopher J. Kirk Brian B. Tuch Shirin Arastu-Kapur Lawrence H. Boise BIOCHEMISTRY OF THE UBIQUITIN-PROTEASOME PATHWAY The ubiquitin proteasome system is involved in the degradation of more than…
Histone Deacetylase Inhibitors and Demethylating Agents
Histone Deacetylase Inhibitors and Demethylating Agents Steven D. Gore Stephen B. Baylin James G. Herman INTRODUCTION The past decade has seen an explosive growth, especially at a genome-wide level, in…
Kinase Inhibitors as Anticancer Drugs
Kinase Inhibitors as Anticancer Drugs Charles L. Sawyers INTRODUCTION In 2001, the first tyrosine-kinase inhibitor imatinib was approved for clinical use in chronic myeloid leukemia. The spectacular success of this…
